An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

985

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Bacterial Conjunctivitis

Interventions

DRUG

Moxifloxacin ophthalmic solution, 0.5%

DRUG

Ofloxacin ophthalmic solution, 0.3%

Trial Locations (1)

Alcon (China) Ophthalmic Product Co., Ltd., Beijing